Cephalexin--a new oral cephalosporin: clinical evaluation in sixty-three patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001991:Bronchitis / Q000188:drug therapy; D002511:Cephalosporins / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D002512:Cephalothin / Q000627:therapeutic use; D004352:Drug Resistance, Microbial / Q000187:drug effects; D006801:Humans; D007612:Kanamycin / Q000627:therapeutic use; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010612:Pharyngitis / Q000188:drug therapy; D011008:Pneumococcal Infections / Q000188:drug therapy; D011014:Pneumonia / Q000188:drug therapy; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy; D011472:Prostatitis / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D002511:Cephalosporins; D007612:Kanamycin; D002512:Cephalothin